Abafungin

Abafungin
Structural formula of abafungin
Space-filling model of the abafungin molecule
Clinical data
Trade namesAbasol
Routes of
administration		Topical (cream)
ATC code
  • none
Identifiers
  • N-[4-[2-(2,4-dimethylphenoxy)phenyl]-1,3-thiazol-2-yl]-1,4,5,6-tetrahydropyrimidin-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.125.129 Edit this at Wikidata
Chemical and physical data
FormulaC21H22N4OS
Molar mass378.49 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1)OC2=CC=CC=C2C3=CSC(=N3)NC4=NCCCN4)C
  • InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25) checkY
  • Key:TYBHXIFFPVFXQW-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Abafungin (INN) is a broad-spectrum arylguanidines-class antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.[1]

Abasol is a topical cream formulation of abafungin by York Pharma.[2]

History

Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H2-antagonists related to famotidine, resulted in the discovery of its antifungal properties.[3]

Its development seems to have been discontinued in 2009.[4]

Mechanism of action

Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[3]

In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[5]

Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[6]

References

  1. ^ Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, et al. (2008). "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 54 (4): 245–259. doi:10.1159/000142334. PMC 2818358. PMID 18587237.
  2. ^ "Regulatory Update – Abasol" (PDF). York Pharma. Archived from the original (PDF) on September 27, 2007.
  3. ^ a b Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, et al. (August 2008). "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 54 (4): 245–259. doi:10.1159/000142334. PMC 2818358. PMID 18587237.
  4. ^ "Abafungin". AdisInsight. Retrieved 5 May 2021.
  5. ^ Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, et al. (December 1995). "ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis". Kidney International. 48 (6): 1778–1791. doi:10.1038/ki.1995.476. PMID 8587237.
  6. ^ Ginter-Hanselmayer G (March 2009). Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten [Working documents for the 42nd scientific training event for pharmacists: Infectious diseases] (in German). Österreichische Apothekerkammer (Austrian Chamber of Pharmacists). p. 103.
  • Media related to Abafungin at Wikimedia Commons
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.